Analysts Set Vaxcyte, Inc. (NASDAQ:PCVX) PT at $147.50

Vaxcyte, Inc. (NASDAQ:PCVX) has been assigned an average rating of “Buy” from the seven analysts that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $147.50.

A number of research analysts recently issued reports on the stock. Jefferies Financial Group raised their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Mizuho raised their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. BTIG Research boosted their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Needham & Company LLC restated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Bank of America lifted their target price on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th.

Insider Activity at Vaxcyte

In other Vaxcyte news, SVP Elvia Cowan sold 5,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the sale, the senior vice president now directly owns 12,723 shares in the company, valued at approximately $1,369,885.41. The trade was a 28.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total value of $927,520.00. Following the transaction, the chief financial officer now owns 90,383 shares in the company, valued at $10,479,005.02. The trade was a 8.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 102,464 shares of company stock worth $11,455,576 over the last quarter. Company insiders own 3.10% of the company’s stock.

Institutional Trading of Vaxcyte

Several hedge funds have recently modified their holdings of PCVX. Riverview Trust Co acquired a new stake in Vaxcyte in the third quarter worth $27,000. Fifth Third Bancorp bought a new position in shares of Vaxcyte during the 2nd quarter worth about $35,000. Blue Trust Inc. grew its stake in shares of Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after buying an additional 93 shares during the period. J.Safra Asset Management Corp increased its position in Vaxcyte by 649.4% in the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after buying an additional 526 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in Vaxcyte in the 2nd quarter valued at about $70,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $88.54 on Friday. The company’s 50 day moving average price is $107.89 and its two-hundred day moving average price is $89.41. The firm has a market capitalization of $11.04 billion, a P/E ratio of -19.25 and a beta of 1.01. Vaxcyte has a fifty-two week low of $48.24 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the prior year, the business posted ($0.91) EPS. On average, analysts expect that Vaxcyte will post -4.14 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.